News

Filter

Current filters:

nintedanib

1 to 9 of 14 results

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

16-10-2014

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech,…

Boehringer IngelheimEsbrietGenentechnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

10-09-2014

A pre-specified subgroup analysis from the two replicate Phase III INPULSI trials, presented today at…

Boehringer IngelheimnintedanibPharmaceuticalResearchRespiratory and Pulmonary

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

Boehringer files for EU approval of nintedanib

Boehringer files for EU approval of nintedanib

15-10-2013

Boehringer Ingelheim has submitted a Marketing Authorization Application to the EMA for the approval…

Boehringer IngelheimEuropenintedanibOncologyPharmaceuticalRegulation

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top